AI and Annotated Medical Images – OpenPath, PLIP, and “Medical Twitter”

By Michael Awood

September 1, 2023

The lack of available annotated medical images has historically hindered healthcare innovation. However, a solution is emerging as healthcare professionals start to share anonymised images and insights on public platforms – which includes the social media site previously known as Twitter (X). This has led to the creation of OpenPath, a comprehensive dataset of over 200,000 pathology images coupled with natural language descriptions, marking it as the largest public dataset of its kind.

Researchers have used OpenPath to develop Pathology Language–Image Pre-training (PLIP), a multimodal AI trained on this dataset. PLIP has demonstrated impressive results in zero-shot learning and transfer learning for classifying new pathology images across various tasks. Additionally, PLIP enables users to locate similar cases using either image or natural language search, encouraging knowledge sharing.

The researchers collected over 240,000 public pathology images using popular pathology-related hashtags and expanded the collection with data from other online sources. After thorough data quality checks, they assembled over 200,000 pathology image-text pairs named OpenPath, which they used to develop the versatile PLIP.

PLIP outperformed previous models in tasks such as zero-shot learning, linear probing, and text-to-image and image-to-image retrieval. Unlike other digital pathology machine learning methods, PLIP can adapt to new datasets and provide zero-shot predictions based on any text input, making it a flexible tool for potential new disease subtypes.

The study did note some limitations, including irrelevant data in the image-text pairs and challenges in accounting for varying magnification levels and staining styles. However, researchers are optimistic that PLIP can adjust to images with diverse magnification levels and staining protocols. They expect that OpenPath and PLIP will significantly contribute to advancing AI in pathology and encourage a data-focused approach in this area.

Reference url

Recent Posts

CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients

By HEOR Staff Writer

November 7, 2025

European Commission Approves Koselugo for Adult NF1 Patients The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential
Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...